Webinar: DT3C for Antibody Internalization in ADC Research

Cancer remains one of the leading causes of death worldwide. According to the latest WHO report, cancer accounts for nearly one in six deaths. Antibody-drug conjugates (ADCs) represent a relatively new class of anticancer therapeutics characterized by high specificity and potent cytotoxic properties. ADCs consist of three key components: a monoclonal antibody, a linker, and a cytotoxic payload. Following specific binding of the antibody to tumor cell surface antigens, ADCs undergo internalization and processing within the endo-lysosomal system to release the potent payload. However, the success of this strategy hinges on efficient antibody internalization. Many antibodies exhibit poor uptake after binding their cell-surface targets, leading to sub-optimal ADC processing and insufficient payload delivery. Consequently, internalization efficiency has emerged as a critical determinant of ADC efficacy.

This webinar will discuss current methods for assessing internalization and introduce a user-friendly tool: the recombinant protein DT3C. DT3C serves as a simple, plate-based reagent enabling the comparative assessment of internalization efficiency among candidate antibodies. By providing a standardized benchmark, DT3C supports the clinical advancement of ADCs for cancer treatment.

Key Points

1. Antibodies to ADCs: Why internalization matters?

2. Introduction to current internalization assays

3. DT3C: A simpler tool for antibody internalization assessment

Webinar Registration

To accommodate our global audience, the webinar will be held at three different times:

September 3, 2025 3:00 pm JST/KST

September 3, 2025 2:00 pm CET

September 3, 2025 11:00 am PDT/ 2:00 pm EDT

Speaker

Ying Zhou PhD

Product Manager, CUSABIO

Join Dr. Ying Zhou, Product Manager at CUSABIO, as she unveils the potential of DT3C to transform ADC development and improve cancer treatment outcomes.